美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Vicore Pharma Holding AB

10.65

-0.0500-0.47%

盤後：10.38-0.2700-2.54%16:10 EDT

成交量：1.45萬

成交額：15.14萬

市值：3.00億

市盈率：-5.46

高：11.20

開：10.70

低：10.16

收：10.70

52周最高：17.80

52周最低：10.16

股本：2,815.26萬

流通股本：1,986.21萬

量比：0.50

換手率：0.07%

股息：- -

股息率：- -

每股收益(TTM):-1.9520

每股收益(LYR):-0.2159

淨資產收益率：-56.99%

總資產收益率：-34.35%

市淨率：3.46

市盈率(LYR):-49.32

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Vicore Pharma Holding AB

交易所：

NASDAQ

成立時間：

2000

員工人數：

46

公司地址：

Kornhamnstorg 53,Stockholm,Stockholm County,Sweden

官網：

http://www.vicorepharma.com

郵編：

111 27

電話：

46 3 17 88 05 60

傳真：

- -

簡介：

Vicore Pharma Holding AB於2005年根據瑞典法律註冊成立為一家股份有限公司。該公司是一家臨床階段的製藥公司，致力於開發呼吸系統疾病和纖維化疾病的治療藥物。其主要候選產品buloxibutid (C21)是一種口服小分子血管緊張素II 2型受體激動劑，已獲得美國食品藥品監督管理局的孤兒藥資格認定和快速通道資格認定，目前正在進行一項針對特發性肺纖維化的全球IIb期臨床試驗。該公司的藥物研發項目基於AT2受體，AT2受體是腎素-血管緊張素系統的一部分，該系統是一種調節血壓和水平衡的激素系統。

董事

名稱

職位

Hans Schikan

Chairman and Director

Ann Barbier

Independent Director

Elisabeth Björk

Independent Director

Heidi Hunter

Independent Director

Jacob Gunterberg

Independent Director

Peter Guenter

Independent Director

Yasir Al Wakeel

Independent Director

股東

名稱

職位

Ahmed Mousa

Chief Executive Officer

Hans Jeppsson

Chief Financial Officer

Bernt van den Blink

Chief Medical Officer

Rob Slack

Chief Scientific Officer

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/VCRE/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"VCRE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VCRE\",,,,,undefined,":{"symbol":"VCRE","market":"US","secType":"STK","nameCN":"Vicore Pharma Holding AB","latestPrice":10.65,"timestamp":1789588800000,"preClose":10.7,"halted":0,"volume":14462,"hourTrading":{"tag":"盘后","latestPrice":10.38,"preClose":10.65,"latestTime":"16:10 EDT","volume":4,"amount":41.52,"timestamp":1789589404578,"change":-0.27,"changeRate":-0.025352,"amplitude":0},"delay":0,"changeRate":-0.004672897196261583,"floatShares":19862100,"shares":28152600,"eps":-1.952,"marketStatus":"盤後交易","change":-0.05,"latestTime":"09-16 19:08:49 EDT","open":10.7,"high":11.2,"low":10.16,"amount":151396,"amplitude":0.097196,"askPrice":11.5,"askSize":100,"bidPrice":8.42,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.952,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":4,"adr":0,"adrRate":10,"exchange":"NASDAQ","adjPreClose":10.7,"postHourTrading":{"tag":"盘后","latestPrice":10.38,"preClose":10.65,"latestTime":"16:10 EDT","volume":4,"amount":41.52,"timestamp":1789589404578,"change":-0.27,"changeRate":-0.025352,"amplitude":0},"volumeRatio":0.502641},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VCRE\",,,,,undefined,":{"symbol":"VCRE","floatShares":19862100,"roa":"-34.35%","roe":"-56.99%","lyrEps":-0.215948,"volumeRatio":0.502641,"shares":28152600,"dividePrice":0,"high":11.2,"amplitude":0.097196,"preClose":10.7,"low":10.16,"week52Low":10.16,"pbRate":"3.46","psRate":"740.26","week52High":17.8,"institutionHeld":0,"latestPrice":10.65,"eps":-1.952,"divideRate":0,"volume":14462,"delay":0,"ttmEps":-1.952,"open":10.7,"prevYearClose":14.9,"prevWeekClose":10.78,"prevMonthClose":11.04,"prevQuarterClose":14.9,"fiveDayClose":12.08,"twentyDayClose":12.23},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VCRE\",params:#limit:5,,,undefined,":[{"date":"2026-11-05","symbol":"VCRE","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1793869200000,"name":null,"time":"盤前","dateTimestamp":1793854800000,"actualEps":null},{"date":"2026-08-21","symbol":"VCRE","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787299200000,"name":null,"time":"盤前","dateTimestamp":1787284800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VCRE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VCRE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.5714,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":7,"updateTime":1774411200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/VCRE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"VCRE","date":"2026-09-15","current":-5.271516,"percent":1,"low":-9.302023,"twenty":-6.834139,"median":-6.596843,"eighty":-6.031618,"high":-5.753477,"avg":-6.630993,"sd":0.63148,"marketCap":295509590.69},"quantilePoints":[{"date":"2026-07-10","current":-7.569758,"twenty":-8.26741,"median":-7.937568,"eighty":-7.607725,"marketCap":371834447.2},{"date":"2026-07-17","current":-6.73922,"twenty":-7.951806,"median":-7.409583,"eighty":-6.864987,"marketCap":331740814.59},{"date":"2026-07-24","current":-6.656167,"twenty":-7.681287,"median":-6.881598,"eighty":-6.732101,"marketCap":323298529.11},{"date":"2026-07-31","current":-6.596843,"twenty":-7.588742,"median":-6.798545,"eighty":-6.618199,"marketCap":327833556.98},{"date":"2026-08-07","current":-6.798545,"twenty":-7.377548,"median":-6.768883,"eighty":-6.587351,"marketCap":339377276.87},{"date":"2026-08-14","current":-6.644302,"twenty":-7.085673,"median":-6.798545,"eighty":-6.618199,"marketCap":329558786.01},{"date":"2026-08-21","current":-6.549383,"twenty":-6.969398,"median":-6.73922,"eighty":-6.573113,"marketCap":327959487.43},{"date":"2026-08-28","current":-5.932923,"twenty":-6.943296,"median":-6.679896,"eighty":-6.544637,"marketCap":312990616.5},{"date":"2026-09-04","current":-6.112368,"twenty":-6.900582,"median":-6.638369,"eighty":-6.112368,"marketCap":321274633.82},{"date":"2026-09-11","current":-5.888061,"twenty":-6.857868,"median":-6.61464,"eighty":-6.112368,"marketCap":305884485.46},{"date":"2026-09-15","current":-5.753477,"twenty":-6.834139,"median":-6.596843,"eighty":-6.031618,"marketCap":295509590.69}],"updateTime":1789577933006},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1427456,"yearFounded":2000,"employeeNum":46,"address":"Kornhamnstorg 53,Stockholm,Stockholm County,Sweden","zipCode":"111 27","officePhone":"46 3 17 88 05 60","fiscalYearEnd":"12-31"},"stockCompanyDetail":{"websiteUrl":"http://www.vicorepharma.com","stockEarnings":[{"period":"1week","weight":-0.1001},{"period":"1month","weight":-0.1725},{"period":"3month","weight":-0.2819},{"period":"ytd","weight":-0.2819}],"compareEarnings":[{"period":"1week","weight":-0.0112},{"period":"1month","weight":-0.0244},{"period":"3month","weight":0.0222},{"period":"6month","weight":0.1479},{"period":"1year","weight":0.146},{"period":"ytd","weight":0.1107}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Vicore Pharma Holding AB於2005年根據瑞典法律註冊成立為一家股份有限公司。該公司是一家臨床階段的製藥公司，致力於開發呼吸系統疾病和纖維化疾病的治療藥物。其主要候選產品buloxibutid (C21)是一種口服小分子血管緊張素II 2型受體激動劑，已獲得美國食品藥品監督管理局的孤兒藥資格認定和快速通道資格認定，目前正在進行一項針對特發性肺纖維化的全球IIb期臨床試驗。該公司的藥物研發項目基於AT2受體，AT2受體是腎素-血管緊張素系統的一部分，該系統是一種調節血壓和水平衡的激素系統。","exchange":"NASDAQ","name":"Vicore Pharma Holding AB","nameEN":"Vicore Pharma Holding AB","securityTypeName":"存托凭证","adrRate":"1:10"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"VCRE\",market:\"US\",,,undefined,":{"directors":[{"name":"Hans Schikan","position":"Chairman and Director"},{"name":"Ann Barbier","position":"Independent Director"},{"name":"Elisabeth Björk","position":"Independent Director"},{"name":"Heidi Hunter","position":"Independent Director"},{"name":"Jacob Gunterberg","position":"Independent Director"},{"name":"Peter Guenter","position":"Independent Director"},{"name":"Yasir Al Wakeel","position":"Independent Director"}],"executives":[{"name":"Ahmed Mousa","position":"Chief Executive Officer"},{"name":"Hans Jeppsson","position":"Chief Financial Officer"},{"name":"Bernt van den Blink","position":"Chief Medical Officer"},{"name":"Rob Slack","position":"Chief Scientific Officer"}]}}}